Death from vascular disease accounts for about one-third of all causes of death. Important
regulatory factors in cardiovascular disease include dyslipidemia, high blood pressure, and
diabetes, and keeping LDL cholesterol low among dyslipidemia levels, especially after
cardiovascular stent treatment, is an essential factor to prevent another event in the
future. Statin is currently the most widely used LDL cholesterol control drug with
multifunctional effects such as controlling inflammatory reactions, controlling the movement
and proliferation of vascular smooth muscle cells, and inhibiting the production of blood
clots in addition to LDL cholesterol control.In addition, in several clinical studies,
statins have shown many effects in primary and secondary prevention of cardiovascular
disease, and several studies have been published that lower LDL cholesterol results in more
benefits. Based on these findings, the 2016 European Heart Association (ESC), 2018 American
Heart Association (ACC), and most recently changed 2022 Korean guidelines recommend
controlling LDL cholesterol to <55mg/dL for patients with coronary artery disease. However,
high-dose statins alone are still difficult to maintain for a long time due to increased
liver levels, diabetes, and muscle pain, and recently, a drug that lowers LDL cholesterol has
been developed in the small intestine called Ezetimib and is widely used in combination with
statins in actual clinical trials. In fact, the RACING trial published in LANCET for domestic
patients reported that the combination of moderate-intensity statins (Rosuvastatin 10mg) and
ezetimib had fewer side effects for three years and better compliance, resulting in a better
rate of maintaining LDL cholesterol at 70mg/dL or less than high-intensity statins alone.
However, in this study, the rate at which LDL cholesterol remained below 55 mg/dL after one
year was only 42% for moderate statins/esetimibe and 25% for high-intensity statins, and
remained similar for three years. Therefore, high-intensity statins and ezetimibes may be
essential treatments to reduce LDL cholesterol to less than 55 mg/dL and more than 50% under
the current new guidelines. High-strength statins usually refer to more than 40 mg of
atovastatin and 20 mg of Rosuvastatin, and drugs that combine ezetimibe with these
high-strength statins are currently widely used to lower LDL cholesterol to 55 mg/dL or less
if there are no special side effects in clinical practice, but research on compliance is very
insufficient. This study aims to observe the rate of discontinuation or intolerance in
patients taking Rosuvastatin/Ezetimib 20/10mg and Atovastatin/Ezetimib 40/10mg, with no
previous comparison, RACING trial reported a 5% rate of discontinuation at rosuvastain 20mg
administered, and atovatin/10mg/10mg. Referring to On the use of a pilot sample for sample
size determination. the hospital conducts about 60 PCI cases a month, and about 1/5 of them
are expected to be able to enroll 100 patients per group for about two years to conduct a
total of 200 patients.